Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways.

Science (New York, N.Y.) - 20 Aug 2004

Sordella Raffaella, Bell Daphne W, Haber Daniel A, Settleman Jeffrey

Abstract excerpt

Gefitinib (Iressa, Astra Zeneca Pharmaceuticals) is a tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR) and induces dramatic clinical responses in nonsmall cell lung cancers (NSCLCs) with activating mutations within the EGFR kinase domain. We report that these mutant EGFRs selectively activate Akt and signal transduction and activator of transcription (STAT) signaling pathways,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Tyrosine
Share to Catalytic Domain
Share to Gefitinib

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Milk Proteins

Share to Mitogen-Activated Protein Kinases

Share to Proto-Oncogene Proteins c-akt

Share to Quinazolines

Share to STAT5 Transcription Factor

Source

Identifiers

PMID: 15284455
DOI: 10.1126/science.1101637

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways.PMID 15284455Read ↗

Somatic mutations of the EGF receptor and their signal transducers affect the efficacy of EGF receptor-specific tyrosine kinase inhibitors.Semantic proximity Read ↗

Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor.Semantic proximity Read ↗

Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics.Semantic proximity Read ↗

EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function.Semantic proximity Read ↗

Inhibition of mutant EGF receptors by gefitinib: targeting an Achilles' heel of lung cancer.Semantic proximity Read ↗

Enhanced gefitinib-induced repression of the epidermal growth factor receptor pathway by ataxia telangiectasia-mutated kinase inhibition in non-small-cell lung cancer cells.Semantic proximity Read ↗

Epidermal growth factor receptor mutations predict sensitivity to gefitinib in patients with non-small-cell lung cancer.Semantic proximity Read ↗

Epidermal growth factor receptor mutations in patients with non-small cell lung cancer.Semantic proximity Read ↗

Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas.Semantic proximity Read ↗

Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells.Semantic proximity Read ↗

STAT3 inhibitor BBI608 enhances the antitumor effect of gefitinib on EGFR-mutated non-small cell lung cancer cells.Semantic proximity Read ↗

Amplification of EGFR Wild-Type Alleles in Non-Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.